{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T12:30:14Z","timestamp":1787056214226,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100018557","name":"Yalova University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018557","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    Newly approved kinase inhibitors (2024\u20132025) have limited post-approval safety data. We developed a weighted ToxPi framework to prioritize multi-endpoint liabilities spanning hERG cardiotoxicity, DILI, Ames genotoxicity, and CYP3A4-mediated drug-drug interaction potential. Thirteen compounds (12 KIs approved in 2024\u20132025 plus imatinib as a historical reference anchor) were profiled using ADMETlab 3.0, vNN-ADMET, and SwissADME (formula inputs) and integrated into a weighted composite (wToxPi\u2009=\u20090.30\u2009\u00d7\u2009hERG\u2009+\u20090.30\u2009\u00d7\u2009DILI\u2009+\u20090.20\u2009\u00d7\u2009Ames\u2009+\u20090.20\u2009\u00d7\u2009CYP3A4). Robustness was assessed across weighting schemes and sensitivity analyses addressing fusion-recoding scenarios, CYP3A4 platform asymmetry, and combination-regimen confounding. DILI signal saturation dominated the cohort: 12 of 13 compounds showed DILIcon\u2009\u2265\u20090.80, limiting hepatic discrimination and shifting differentiation to hERG and Ames variability. Sevabertinib (0.860), Zongertinib (0.840), and Lazertinib (0.775) ranked highest, whereas Mirdametinib (0.080) was the structural outlier. Ranking remained stable: ADMETlab-only and thresholded majority-vote alternatives preserved the principal structure (Spearman\n                    <jats:italic>\u03c1<\/jats:italic>\n                    \u2009=\u20090.780 and 0.812), whereas soft-label pseudo-probability mapping showed near-identity concordance (\n                    <jats:italic>\u03c1<\/jats:italic>\n                    \u2009=\u20090.978); a broader sensitivity grid (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.60\u20130.90) confirmed structural stability (\n                    <jats:italic>\u03c1<\/jats:italic>\n                    \u2009=\u20090.929\u20130.995). Exploratory FAERS findings provided supportive post-marketing context. This framework provides transparent, reproducible, hypothesis-generating prioritization of newly approved KIs. Class-level DILI saturation reinforces the need for close hepatic surveillance in pharmacovigilance interpretation regardless of composite rank; hERG and Ames provide the main inter-compound discriminatory signal. Sevabertinib, Zongertinib, and Lazertinib ranked highest, whereas Mirdametinib was the structural outlier; for Inavolisib and Tovorafenib, endpoint-specific hepatic surveillance remains warranted irrespective of composite rank. The model should support pharmacovigilance prioritization rather than replace clinical monitoring or individualized risk assessment.\n                  <\/jats:p>","DOI":"10.1007\/s10637-026-01615-1","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T06:56:15Z","timestamp":1777704975000},"page":"253-263","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Class-level DILI saturation and hERG-driven risk stratification among 2024\u20132025 FDA-approved kinase inhibitors: an in silico multi-platform safety analysis"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9205-1467","authenticated-orcid":false,"given":"Nihan","family":"K\u00fc\u00e7\u00fck Y\u0131lmaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1733-2621","authenticated-orcid":false,"given":"Veysel","family":"Bask\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"key":"1615_CR1","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/s41573-021-00252-y","volume":"20","author":"M Attwood","year":"2021","unstructured":"Attwood M, Fabbro D, Sokolov A, Knapp S, Schi\u00f6th H (2021) Trends in kinase drug discovery: targets, indications and inhibitor design. Nat Rev Drug Discov 20:839\u2013861. https:\/\/doi.org\/10.1038\/s41573-021-00252-y","journal-title":"Nat Rev Drug Discov"},{"key":"1615_CR2","unstructured":"U.S. Food and Drug Administration (2025) HYRNUO (sevabertinib) tablets, for oral use. Prescribing information. AccessData FDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219972s000lblCorrected.pdf. Accessed April 2026"},{"key":"1615_CR3","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40164-025-00660-5","volume":"14","author":"S Zhu","year":"2025","unstructured":"Zhu S, Fu K, Li S et al (2025) Cardiotoxicity of small-molecule kinase inhibitors in cancer therapy. Exp Hematol Oncol 14:68. https:\/\/doi.org\/10.1186\/s40164-025-00660-5","journal-title":"Exp Hematol Oncol"},{"key":"1615_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1021\/acs.chemrestox.9b00387","volume":"33","author":"SD Lamore","year":"2020","unstructured":"Lamore SD, Kohnken RA, Peters MF, Kolaja KL (2020) Cardiovascular toxicity induced by kinase inhibitors: mechanisms and preclinical approaches. Chem Res Toxicol 33:13\u201326. https:\/\/doi.org\/10.1021\/acs.chemrestox.9b00387","journal-title":"Chem Res Toxicol"},{"key":"1615_CR5","unstructured":"U.S. Food and Drug Administration (2022) E14 and S7B Clinical and Nonclinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential--Questions and Answers. Guidance for Industry. FDA, Silver Spring, MD. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/e14-and-s7b-clinical-and-nonclinical-evaluation-qtqtc-interval-prolongation-and-proarrhythmic. Accessed April 2026"},{"key":"1615_CR6","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nature04710","volume":"440","author":"MC Sanguinetti","year":"2006","unstructured":"Sanguinetti MC, Tristani-Firouzi M (2006) hERG potassium channels and cardiac arrhythmia. Nature 440:463\u2013469. https:\/\/doi.org\/10.1038\/nature04710","journal-title":"Nature"},{"key":"1615_CR7","doi-asserted-by":"publisher","first-page":"4882","DOI":"10.3390\/ijms22094882","volume":"22","author":"R Teschke","year":"2021","unstructured":"Teschke R, Eickhoff A (2021) Drug-induced liver injury: a primary toxicity concept. Int J Mol Sci 22:4882. https:\/\/doi.org\/10.3390\/ijms22094882","journal-title":"Int J Mol Sci"},{"key":"1615_CR8","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1055\/s-0034-1371091","volume":"34","author":"A Regev","year":"2014","unstructured":"Regev A (2014) Drug-induced liver injury and drug development: industry perspective. Semin Liver Dis 34:227\u2013239. https:\/\/doi.org\/10.1055\/s-0034-1371091","journal-title":"Semin Liver Dis"},{"key":"1615_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0027-5107(00)00064-6","volume":"455","author":"K Mortelmans","year":"2000","unstructured":"Mortelmans K, Zeiger E (2000) The Ames Salmonella\/microsome mutagenicity assay. Mutat Res 455:29\u201360. https:\/\/doi.org\/10.1016\/S0027-5107(00)00064-6","journal-title":"Mutat Res"},{"key":"1615_CR10","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.jhep.2015.04.016","volume":"63","author":"M Chen","year":"2015","unstructured":"Chen M, Suzuki A, Borlak J, Andrade RJ, Lucena MI (2015) Drug-induced liver injury: interactions between drug properties and host factors. J Hepatol 63:503\u2013514. https:\/\/doi.org\/10.1016\/j.jhep.2015.04.016","journal-title":"J Hepatol"},{"key":"1615_CR11","doi-asserted-by":"publisher","first-page":"47536","DOI":"10.1021\/acsomega.2c05693","volume":"7","author":"CN Cavasotto","year":"2022","unstructured":"Cavasotto CN, Scardino V (2022) Machine learning toxicity prediction: latest advances by toxicity end point. ACS Omega 7:47536\u201347546. https:\/\/doi.org\/10.1021\/acsomega.2c05693","journal-title":"ACS Omega"},{"key":"1615_CR12","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1289\/ehp.1002180","volume":"118","author":"DM Reif","year":"2010","unstructured":"Reif DM, Martin MT, Tan SW et al (2010) Endocrine profiling and prioritization of environmental chemicals using ToxCast data. Environ Health Perspect 118:1714\u20131720. https:\/\/doi.org\/10.1289\/ehp.1002180","journal-title":"Environ Health Perspect"},{"key":"1615_CR13","doi-asserted-by":"publisher","DOI":"10.1787\/9789264043466-en","author":"OECD","year":"2008","unstructured":"OECD (2008) Handbook on constructing composite indicators: methodology and user guide. OECD Publishing, Paris. https:\/\/doi.org\/10.1787\/9789264043466-en","journal-title":"OECD Publishing, Paris"},{"key":"1615_CR14","doi-asserted-by":"publisher","first-page":"W199","DOI":"10.1093\/nar\/gkae237","volume":"52","author":"L Fu","year":"2024","unstructured":"Fu L, Shi S, Yi J et al (2024) ADMETlab 3.0: an updated comprehensive online ADMET prediction platform enhanced with broader coverage. Nucleic Acids Res 52:W199\u2013W207. https:\/\/doi.org\/10.1093\/nar\/gkae237","journal-title":"Nucleic Acids Res"},{"key":"1615_CR15","doi-asserted-by":"publisher","first-page":"889","DOI":"10.3389\/fphar.2017.00889","volume":"8","author":"P Schyman","year":"2017","unstructured":"Schyman P, Printz RL, Estes SK et al (2017) vNN web server for ADMET predictions. Front Pharmacol 8:889. https:\/\/doi.org\/10.3389\/fphar.2017.00889","journal-title":"Front Pharmacol"},{"key":"1615_CR16","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1021\/acs.chemrestox.3c00281","volume":"37","author":"IH Sanches","year":"2024","unstructured":"Sanches IH, Braga RC, Alves VM, Andrade CH (2024) Enhancing hERG risk assessment with interpretable classificatory and regression models. Chem Res Toxicol 37:387\u2013397. https:\/\/doi.org\/10.1021\/acs.chemrestox.3c00281","journal-title":"Chem Res Toxicol"},{"key":"1615_CR17","doi-asserted-by":"publisher","first-page":"W513","DOI":"10.1093\/nar\/gkae303","volume":"52","author":"P Banerjee","year":"2024","unstructured":"Banerjee P, Kemmler E, Dunkel M, Preissner R (2024) ProTox 3.0: webserver for prediction of toxicity of chemicals. Nucleic Acids Res 52:W513\u2013W520. https:\/\/doi.org\/10.1093\/nar\/gkae303","journal-title":"Nucleic Acids Res"},{"key":"1615_CR18","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","volume":"7","author":"A Daina","year":"2017","unstructured":"Daina A, Michielin O, Zoete V (2017) SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness. Sci Rep 7:42717. https:\/\/doi.org\/10.1038\/srep42717","journal-title":"Sci Rep"},{"key":"1615_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","volume":"46","author":"CA Lipinski","year":"2001","unstructured":"Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3\u201326. https:\/\/doi.org\/10.1016\/S0169-409X(00)00129-0","journal-title":"Adv Drug Deliv Rev"},{"key":"1615_CR20","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.chembiol.2014.08.013","volume":"21","author":"BC Doak","year":"2014","unstructured":"Doak BC, Over B, Giordanetto F, Kihlberg J (2014) Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates. Chem Biol 21:1115\u20131142. https:\/\/doi.org\/10.1016\/j.chembiol.2014.08.013","journal-title":"Chem Biol"},{"key":"1615_CR21","doi-asserted-by":"publisher","first-page":"830","DOI":"10.2174\/1389200219666180523095355","volume":"19","author":"L Kuna","year":"2018","unstructured":"Kuna L, Bozic I, Kizivat T et al (2018) Models of drug induced liver injury (DILI) \u2013 current issues and future perspectives. Curr Drug Metab 19:830\u2013838. https:\/\/doi.org\/10.2174\/1389200219666180523095355","journal-title":"Curr Drug Metab"},{"key":"1615_CR22","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1056\/NEJMoa2503704","volume":"392","author":"JV Heymach","year":"2025","unstructured":"Heymach JV, Ruiter G, Ahn MJ et al (2025) Zongertinib in previously treated HER2-mutant non-small-cell lung cancer. N Engl J Med 392:2321\u20132333. https:\/\/doi.org\/10.1056\/NEJMoa2503704","journal-title":"N Engl J Med"},{"key":"1615_CR23","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","volume":"391","author":"BC Cho","year":"2024","unstructured":"Cho BC, Lu S, Felip E et al (2024) Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC. N Engl J Med 391:1486\u20131498. https:\/\/doi.org\/10.1056\/NEJMoa2403614","journal-title":"N Engl J Med"},{"key":"1615_CR24","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1200\/JCO-25-00275","volume":"43","author":"M Perol","year":"2025","unstructured":"Perol M, Li W, Pennell NA et al (2025) Taletrectinib in ROS1+ non-small cell lung cancer: TRUST. J Clin Oncol 43:1920\u20131929. https:\/\/doi.org\/10.1200\/JCO-25-00275","journal-title":"J Clin Oncol"},{"key":"1615_CR25","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S2213-2600(23)00379-X","volume":"12","author":"M Wang","year":"2024","unstructured":"Wang M, Zhou C, Ohe Y et al (2024) Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): a single-arm, multicentre, phase 2 trial. Lancet Respir Med 12:217\u2013224. https:\/\/doi.org\/10.1016\/S2213-2600(23)00379-X","journal-title":"Lancet Respir Med"},{"key":"1615_CR26","unstructured":"U.S. Food and Drug Administration (2025) AVMAPKI FAKZYNJA CO-PACK (avutometinib capsules; defactinib tablets), co-packaged for oral use. Prescribing information. AccessData FDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219616s000lbl.pdf. Accessed April 2026"},{"key":"1615_CR27","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1001\/jamaoncol.2021.3523","volume":"7","author":"L Horn","year":"2021","unstructured":"Horn L, Wang Z, Wu G et al (2021) Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer: a randomized clinical trial (eXalt3). JAMA Oncol 7:1617\u20131625. https:\/\/doi.org\/10.1001\/jamaoncol.2021.3523","journal-title":"JAMA Oncol"},{"key":"1615_CR28","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","volume":"394","author":"WD Tap","year":"2019","unstructured":"Tap WD, Gelderblom H, Palmerini E et al (2019) Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN). Lancet 394:478\u2013487. https:\/\/doi.org\/10.1016\/S0140-6736(19)30764-0","journal-title":"Lancet"},{"key":"1615_CR29","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","volume":"391","author":"NC Turner","year":"2024","unstructured":"Turner NC, Im SA, Saura C et al (2024) Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer (INAVO120). N Engl J Med 391:1584\u20131596. https:\/\/doi.org\/10.1056\/NEJMoa2404625","journal-title":"N Engl J Med"},{"key":"1615_CR30","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41591-023-02668-y","volume":"30","author":"LB Kilburn","year":"2024","unstructured":"Kilburn LB, Khuong-Quang DA, Hansford JR et al (2024) The type II RAF inhibitor tovorafenib in relapsed\/refractory pediatric low-grade glioma (FIREFLY-1). Nat Med 30:207\u2013217. https:\/\/doi.org\/10.1038\/s41591-023-02668-y","journal-title":"Nat Med"},{"key":"1615_CR31","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1200\/JCO.24.01034","volume":"43","author":"CL Moertel","year":"2025","unstructured":"Moertel CL, Hirbe AC, Shuhaiber HH et al (2025) ReNeu: a pivotal, phase IIb trial of mirdametinib in adults and children with symptomatic neurofibromatosis type 1-associated plexiform neurofibroma. J Clin Oncol 43:716\u2013729. https:\/\/doi.org\/10.1200\/JCO.24.01034","journal-title":"J Clin Oncol"},{"key":"1615_CR32","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3390\/cancers11040553","volume":"11","author":"G Varricchi","year":"2019","unstructured":"Varricchi G, Ameri P, Cadeddu C et al (2019) Antitumour versus cardiotoxicity of anti-HER2 agents: the issue of selectivity. Cancers 11:553. https:\/\/doi.org\/10.3390\/cancers11040553","journal-title":"Cancers"},{"key":"1615_CR33","unstructured":"U.S. Food and Drug Administration (2016) GLEEVEC (imatinib mesylate) tablets label. AccessData FDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/021588s047lbl.pdf. Accessed April 2026"},{"key":"1615_CR34","unstructured":"U.S. Food and Drug Administration (2024) OJEMDA (tovorafenib) tablets, for oral use; OJEMDA (tovorafenib) for oral suspension. Prescribing information. AccessData FDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/218033s000lbl.pdf. Accessed April 2026"},{"key":"1615_CR35","unstructured":"U.S. Food and Drug Administration (2025) HERNEXEOS (zongertinib) tablets, for oral use. Prescribing information. AccessData FDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219042s000lbl.pdf. Accessed April 2026"},{"key":"1615_CR36","unstructured":"U.S. Food and Drug Administration (2025) LAZCLUZE (lazertinib) tablets, for oral use. Prescribing information. AccessData FDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219008s003lbl.pdf. Accessed April 2026"},{"key":"1615_CR37","unstructured":"U.S. Food and Drug Administration (2025) IBTROZI (taletrectinib) capsules, for oral use. Prescribing information. AccessData FDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219713s000lbl.pdf. Accessed April 2026"},{"key":"1615_CR38","unstructured":"U.S. Food and Drug Administration (2025) ZEGFROVY (sunvozertinib) tablets, for oral use. Prescribing information. AccessData FDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219839s000lbl.pdf. Accessed April 2026"},{"key":"1615_CR39","unstructured":"U.S. Food and Drug Administration (2026) ENSACOVE (ensartinib) capsules, for oral use. Prescribing information. AccessData FDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/218171s003lbl.pdf. Accessed April 2026"},{"key":"1615_CR40","unstructured":"U.S. Food and Drug Administration (2025) ROMVIMZA (vimseltinib) capsules, for oral use. Prescribing information. AccessData FDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219304s000lbl.pdf. Accessed April 2026"},{"key":"1615_CR41","unstructured":"U.S. Food and Drug Administration (2024) ITOVEBI (inavolisib) tablets, for oral use. Prescribing information. AccessData FDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/219249s000lbl.pdf. Accessed April 2026"},{"key":"1615_CR42","unstructured":"U.S. Food and Drug Administration (2025) GOMEKLI (mirdametinib) capsules and tablets for oral suspension. Prescribing information. AccessData FDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219379Orig1s000lbl.pdf. Accessed April 2026"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-026-01615-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-026-01615-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-026-01615-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T12:08:13Z","timestamp":1787054893000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-026-01615-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1615"],"URL":"https:\/\/doi.org\/10.1007\/s10637-026-01615-1","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]},"assertion":[{"value":"16 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study is entirely in silico and does not involve human participants, animal subjects, or biological material. No ethics committee approval or informed consent was required.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}